Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CLU |
| Gene Name: | CLU |
| Protein Full Name: | Clusterin |
| Alias: | Aging-associated gene 4 protein;Apolipoprotein J;Complement cytolysis inhibitor;Complement-associated protein SP-40,40;Ku70-binding protein 1;NA1/NA2;Testosterone-repressed prostate message 2;ApoJalpha;Complement cytolysis inhibitor a chain;ApoJbeta |
| Mass (Da): | 52495 |
| Number AA: | 449 |
| UniProt ID: | P10909 |
| Locus ID: | 1191 |
| COSMIC ID: | CLU |
| Gene location on chromosome: | 8p21.1 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.51 |
| Normal role description: | CLU appears to have two different isoforms with different subcellular localization and different function. Secreted CLU appears to protect cells against apoptosis whereas cytosolic/nuclear CLU react with ubiquitin complex and promote protein degradation and cellular apoptosis. Therefore, CLU appears to function both as a OG and TSP depending on the isoform and cell system. Expression levels vary with chemotherapy and also appear to dictate sensitivity to chemotherapy. |